JP2024525044A - Ｉｌ－１７モジュレータとしてのイミダゾトリアジン誘導体 - Google Patents

Ｉｌ－１７モジュレータとしてのイミダゾトリアジン誘導体 Download PDF

Info

Publication number
JP2024525044A
JP2024525044A JP2023580802A JP2023580802A JP2024525044A JP 2024525044 A JP2024525044 A JP 2024525044A JP 2023580802 A JP2023580802 A JP 2023580802A JP 2023580802 A JP2023580802 A JP 2023580802A JP 2024525044 A JP2024525044 A JP 2024525044A
Authority
JP
Japan
Prior art keywords
formula
mmol
alkyl
substituents
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525044A5 (https=
Inventor
ニール ブレイス、ガレス
クリストファー ブルッキングス、ダニエル
チュウ、シュユ
リー コナリー、リッキー
マリー フォーリー、アンネ
リチャード フロスト、ジェイムズ
オリビア ガリモア、エレン
ゴールドスミス、ポール
アンドリュー ジョンソン、ジェイムズ
トーマス ロイバーソン、ジェイムズ
ストレイカー、ロバート
デイビッド テイラー、リチャード
ピエロ シュタージ、ルイージ
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2109520.3A external-priority patent/GB202109520D0/en
Priority claimed from GBGB2203876.4A external-priority patent/GB202203876D0/en
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2024525044A publication Critical patent/JP2024525044A/ja
Publication of JP2024525044A5 publication Critical patent/JP2024525044A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023580802A 2021-07-01 2022-06-30 Ｉｌ－１７モジュレータとしてのイミダゾトリアジン誘導体 Pending JP2024525044A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2109520.3A GB202109520D0 (en) 2021-07-01 2021-07-01 Therapeutic agents
GB2109520.3 2021-07-01
GBGB2203876.4A GB202203876D0 (en) 2022-03-21 2022-03-21 Therapeutic agents
GB2203876.4 2022-03-21
PCT/EP2022/068165 WO2023275301A1 (en) 2021-07-01 2022-06-30 Imidazotriazine derivatives as il-17 modulators

Publications (2)

Publication Number Publication Date
JP2024525044A true JP2024525044A (ja) 2024-07-09
JP2024525044A5 JP2024525044A5 (https=) 2025-06-25

Family

ID=82493962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580802A Pending JP2024525044A (ja) 2021-07-01 2022-06-30 Ｉｌ－１７モジュレータとしてのイミダゾトリアジン誘導体

Country Status (6)

Country Link
US (1) US20240294534A1 (https=)
EP (1) EP4363421A1 (https=)
JP (1) JP2024525044A (https=)
AR (1) AR126255A1 (https=)
TW (1) TW202317576A (https=)
WO (1) WO2023275301A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
GB202218846D0 (en) 2022-12-14 2023-01-25 UCB Biopharma SRL Therapeutic agents
GB202218860D0 (en) 2022-12-14 2023-01-25 Ucb Biopharma Sprl Therapeutic agents
WO2024126249A1 (en) 2022-12-14 2024-06-20 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
PE20252337A1 (es) * 2023-02-13 2025-10-02 Dice Alpha Inc Moduladores de il-17a de imidazotriazina y usos de estos
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
GB202305585D0 (en) 2023-04-17 2023-05-31 UCB Biopharma SRL Therapeutic agents
GB202305587D0 (en) 2023-04-17 2023-05-31 UCB Biopharma SRL Therapeutic agents
CN117551093B (zh) * 2023-11-14 2024-06-18 山东天锐医药科技有限公司 马来酸阿伐曲泊帕起始原料4-(4-氯-2-噻吩基)-2-噻唑胺的制备方法
WO2026012492A1 (en) * 2024-07-12 2026-01-15 Anew Therapeutics Pte. Ltd. Heterocyclic compounds as il-17 inhibitors
WO2026039168A1 (en) * 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039172A1 (en) * 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039167A1 (en) * 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039170A1 (en) * 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039171A1 (en) * 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026073937A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
WO2026073936A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
WO2026073929A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020261141A1 (en) * 2019-06-26 2020-12-30 UCB Biopharma SRL Imidazopyridine derivatives as il-17 modulators

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2242504B1 (en) 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
JP2020516440A (ja) 2016-11-22 2020-06-11 ヘパトケム，インコーポレイテッド 光化学デバイス
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
US11472794B2 (en) 2018-01-15 2022-10-18 UCB Biopharma SRL Fused imidazole derivatives as IL-17 modulators
CN110511213B (zh) 2018-05-22 2021-10-19 成都先导药物开发股份有限公司 一种免疫调节剂
EP3820567A1 (en) 2018-07-12 2021-05-19 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
US20220162191A1 (en) 2019-03-08 2022-05-26 Leo Pharma A/S Small molecule modulators of il-17
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN112341439B (zh) 2019-08-09 2022-02-15 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341441B (zh) 2019-08-09 2022-02-11 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341446B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021098844A1 (zh) 2019-11-20 2021-05-27 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204801A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
US20230399328A1 (en) 2020-11-09 2023-12-14 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
EP4259631A1 (en) 2020-12-14 2023-10-18 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020261141A1 (en) * 2019-06-26 2020-12-30 UCB Biopharma SRL Imidazopyridine derivatives as il-17 modulators

Also Published As

Publication number Publication date
EP4363421A1 (en) 2024-05-08
AR126255A1 (es) 2023-10-04
WO2023275301A1 (en) 2023-01-05
TW202317576A (zh) 2023-05-01
US20240294534A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
JP2024525044A (ja) Ｉｌ－１７モジュレータとしてのイミダゾトリアジン誘導体
ES2963417T3 (es) Derivados de imidazol condensados como moduladores de IL-17
JP7827725B2 (ja) Ｉｌ－１７モジュレータとしてのイミダゾピリダジン誘導体
EP3638227B1 (en) Spirocyclic indolines as il-17 modulators
CA2677572C (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
JP7682920B2 (ja) Ｉｌ－１７モジュレータとしてのジフルオロシクロヘキシル誘導体
WO2021170631A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
JP7620333B2 (ja) シアノ基により置換された環状ヒドラジン誘導体及びその使用
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
WO2021170627A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
WO2022096411A1 (en) Dicyclopropylmethyl derivatives as il-17 modulators
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
WO2024017880A1 (en) Imidazotriazine derivatives as il-17 modulators
EP4305040A1 (en) Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors
CN116583521A (zh) 作为il-17调节剂的咪唑并哒嗪衍生物
WO2026033047A1 (en) Benzothiadiazine derivatives as mrgx2 antagonists
CN121127467A (zh) 作为ripk1抑制剂的异噁唑烷及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260304